期刊文献+

LncRNA ITGA9-AS1在卵巢癌中的表达及与顺铂化疗敏感性的关系 被引量:2

Expression of LncRNA ITGA9-AS1 in ovarian cancer and its relationship with chemosensitivity to cisplatin
下载PDF
导出
摘要 目的:观察长链非编码RNA(LncRNA)ITGA9-AS1在卵巢癌中的表达水平,探究其与顺铂化疗敏感性的关系。方法:选取2017年01月至2019年01月本院收治的64例卵巢癌患者,卵巢摘除手术中采集卵巢癌组织,另收集因卵巢囊肿需作手术切除但已证实无瘤细胞的正常卵巢组织标本,采用实时定量PCR(RT-qPCR)检测卵巢癌及正常卵巢组织、顺铂(DDP)耐药卵巢癌细胞SKOV3/DDP、卵巢癌细胞(OVCAR5、OVCAR8、SKOV3)及永生化卵巢上皮细胞(IOSE29、IOSE80)中LncRNA ITGA9-AS1表达水平。采用慢病毒介导LncRNA ITGA9-AS1转染并筛选稳定细胞株,MTT法检测过表达LncRNA ITGA9-AS1对SKOV3、SKOV3/DDP增殖的影响及对不同浓度(0、1、2、4、8、16 mg/L)DDP的敏感性。结果:与正常卵巢组织比较,卵巢癌组织中LncRNA ITGA9-AS1表达水平降低(P<0.05)。与IOSE29、IOSE80细胞比较,OVCAR5、OVCAR8、SKOV3及SKOV3/DDP细胞中LncRNA ITGA9-AS1表达水平显著降低(P<0.05);与SKOV3细胞比较,SKOV3/DDP细胞中LncRNA ITGA9-AS1表达水平显著降低(P<0.05)。与空白对照组及慢病毒对照组比较,慢病毒过表达组SKOV3、SKOV3/DDP细胞中LncRNA ITGA9-AS1表达水平升高(P<0.05),增殖率降低(P<0.05),细胞存活率呈DDP浓度依赖降低(P<0.05)。结论:LncRNA ITGA9-AS1在卵巢癌组织及癌细胞中低表达,过表达LncRNA ITGA9-AS1可增加卵巢癌SKOV3及卵巢癌顺铂耐药细胞SKOV3/DDP的顺铂化疗敏感性。 Objective:To observe the expression level of long non-coding RNA(LncRNA)ITGA9-AS1 in ovarian cancer and explore its relationship with the chemosensitivity of cisplatin.Methods:64 patients with ovarian cancer admitted to our hospital from January 2017 to January 2019 were selected,and the ovarian cancer tissues were collected during ovariectomy.In addition,normal ovarian tissue specimens with proven tumor-free cells were selected because of the need for surgical excision of ovarian cysts.The expression level of LncRNA ITGA9-AS1 in ovarian cancer and normal ovarian tissues,cisplatin-resistant ovarian cancer SKOV3/DDP cells,ovarian cancer cells(OVCAR5,OVCAR8,SKOV3)and immortalized ovarian epithelial cells(IOSE29,IOSE80)were detected by real-time quantitative PCR.LncRNA ITGA9-AS1 was transfected by lentivirus and stable cell lines were screened.MTT assay was used to detect the effects of overexpression of LncRNA ITGA9-AS1 on proliferations of SKOV3 and SKOV3/DDP and their sensitivities to DDP at different concentrations(0,1,2,4,8,16 mg/L).Results:Compared with normal ovarian tissues,the expression level of LncRNA ITGA9-AS1 in ovarian cancer tissues was significantly lower(P<0.05).Compared with IOSE29 and IOSE80 cells,the expression level of LncRNA ITGA9-AS1 in OVCAR5,OVCAR8,SKOV3 and SKOV3/DDP cells was significantly lower(P<0.05),and compared with SKOV3 cells,the expression level of LncRNA ITGA9-AS1 in SKOV3/DDP cells was significantly lower(P<0.05).Compared with the blank control group and the lentivirus control group,the expression level of LncRNA ITGA9-AS1 in SKOV3 and SKOV3/DDP cells in the lentivirus overexpression group increased significantly(P<0.05).The proliferation rate decreased significantly(P<0.05),and the cell survival rate decreased in a concentration-dependent manner(P<0.05).Conclusion:LncRNA ITGA9-AS1 is low expressed in ovarian cancer tissues and cancer cells.Overexpression of LncRNA ITGA9-AS1 can increase the chemosensitivity of ovarian cancer SKOV3 and ovarian cancer cisplatin cell SKOV3/DDP to cisplatin.
作者 樊素珍 秦巧红 郜翔 李红雨 赵书君 FAN Suzhen;QIN Qiaohong;GAO Xiang;LI Hongyu;ZHAO Shujun(Gynecological Neoplasm Area,the Third Affiliated Hospital of Zhengzhou University,Henan Zhengzhou 450000,China)
出处 《现代肿瘤医学》 CAS 北大核心 2021年第15期2673-2677,共5页 Journal of Modern Oncology
关键词 卵巢癌 长链非编码RNA ITGA9-AS1 顺铂 敏感性 ovarian cancer long non-coding RNA ITGA9-AS1 cisplatin sensitivity
  • 相关文献

参考文献15

二级参考文献89

  • 1周宏灏.药理学[M].2版.北京:科学出版社,2008:230.
  • 2Mantia-Smaldone GM,Edwards RP,Vlad AM.Targeted treatment of recurrent platinum-resistant ovarian cancer:current and emerging therapies[J].Cancer Manag Res,2011,3:25-38.
  • 3Ushijima K.Treatment for recurrent ovarian cancer-at first relapse[J].J Oncol,2010,2010:497429.
  • 4Monk BJ,Coleman RL.Changing the paradigm in the treatment of platinum-sensitive recurrent ovarian cancer:from platinum doublets to nonplatinum doublets and adding antiangiogenesis compounds[J].Int J Gynecol Cancer,2009,19(Suppl 2):63-67.
  • 5Leamon CP,Lovejoy CD,Nguyen B.Patient selection and targeted treatment in the management of platinum-resistant ovarian cancer[J].Pharmgenomics Pers Med,2013,6:113-125.
  • 6Schiff PB,Fant J,Horwitz SB.Promotion of microtubule assembly in vitro by taxol[J].Nature,1979,277(5698):665-667.
  • 7Gynecologic Oncology Group,Markman M,Blessing J,et al.Phase II trial of weekly paclitaxel(80 mg/m2)in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers:a Gynecologic Oncology Group study[J].Gynecol Oncol,2006,101(3):436-440.
  • 8Rosenberg P,Andersson H,Boman K,et al.Randomized trial of single agent paclitaxel given weekly versus every three weeks and with peroral versus intravenous steroid premedication to patients with ovarian cancer previously treated with platinum[J].Acta Oncol,2002,41(5):418-424.
  • 9Lortholary A,Largillier R,Weber B,et al.Weekly paclitaxel as a single agent or in combination with carboplatin or weekly topotecan in patients with resistant ovarian cancer:the CARTAXHY randomized phase II trial from Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens(GINECO)[J].Ann Oncol,2012,23(2):346-352.
  • 10ten Bokkel Huinink W,Gore M,Carmichael J,et al.Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer[J].J Clin Oncol,1997,15(6):2183-2193.

共引文献91

同被引文献22

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部